NCT04351334View on ClinicalTrials.gov

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

CompletedOBSERVATIONAL
Enrollment

161

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions
Non-Small-Cell Lung Carcinoma
Interventions
DRUG

Alectinib

Observational treatment based on physician choice

Trial Locations (1)

10017

Pfizer Inc, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY